{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:10:40Z","timestamp":1792188640432,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s12020-018-1823-x","type":"journal-article","created":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T16:40:20Z","timestamp":1543682420000},"page":"308-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapy of moderate-to-severe Graves\u2019 orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density"],"prefix":"10.1007","volume":"64","author":[{"given":"Joanna","family":"Rymuza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Popow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"\u017burecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Przedlacki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Bednarczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Mi\u015bkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,1]]},"reference":[{"key":"1823_CR1","doi-asserted-by":"publisher","first-page":"402","DOI":"10.5603\/EP.2014.0056","volume":"65","author":"P Mi\u015bkiewicz","year":"2014","unstructured":"P. Mi\u015bkiewicz, A. Kryczka, U. Ambroziak, B. Rutkowska, R. G\u0142\u00f3wczy\u0144ska, G. Opolski, G. Kahaly, T. Bednarczuk, Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe? Endokrynol. Pol. 65, 402\u2013413 (2014)","journal-title":"Endokrynol. Pol."},{"key":"1823_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","volume":"5","author":"L Bartalena","year":"2016","unstructured":"L. Bartalena, L. Baldeschi, K. Boboridis, A. Eckstein, G.J. Kahaly, C. Marcocci, P. Perros, M. Salvi, W. Wiersinga, The 2016 European Thyroid Association\/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy. Eur. Thyroid J. 5, 9\u201326 (2016)","journal-title":"Eur. Thyroid J."},{"key":"1823_CR3","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1210\/jc.2009-0376","volume":"94","author":"H Stiebel-Kalish","year":"2009","unstructured":"H. Stiebel-Kalish, E. Robenshtock, M. Hasanreisoglu, D. Ezrachi, I. Shimon, L. Leibovici, Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 94, 2708\u20132716 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1823_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1530\/EJE-11-0779","volume":"166","author":"C Marcocci","year":"2012","unstructured":"C. Marcocci, T. Watt, M.A. Altea, A.K. Rasmussen, U. Feldt-Rasmussen, J. Orgiazzi, L. Bartalena; European Group of Graves' Orbitopathy, Fatal and non-fatal adverse events of glucocorticoid therapy for Graves' orbitopathy: a questionnaire survey among members of the European Thyroid Association. Eur. J. Endocrinol. 166, 247\u2013253 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"1823_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12020-016-0928-3","volume":"54","author":"M Moleti","year":"2016","unstructured":"M. Moleti, G. Giuffrida, G. Sturnilo, G. Squadrito, A. Campenni, S. Morelli, E. Puxeddu, E. Sisti, F. Trimarchi, F. Vermiglio, M. Marin\u00f2, Acute liver damage following intravenous glucocorticoid treatment for Graves\u2019 ophthalmopathy. Endocrine 54, 256\u2013268 (2016)","journal-title":"Endocrine"},{"key":"1823_CR6","first-page":"1","volume":"36","author":"P Miskiewicz","year":"2018","unstructured":"P. Miskiewicz, J. Milczarek-Banach, B. Rutkowska-Hinc, A. Kondracka, T. Bednarczuk, High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII. J. Endocrinol. Invest. 36, 1\u20139 (2018).","journal-title":"J. Endocrinol. Invest."},{"key":"1823_CR7","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.3390\/ijms19102918","volume":"19","author":"P Miskiewicz","year":"2018","unstructured":"P. Miskiewicz, J. Milczarek-Banach, T. Bednarczuk, G. Opolski, R. Gl\u00a2wczynska, Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy. Int. J. Mol. Sci. 19, 2918 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"1823_CR8","doi-asserted-by":"publisher","first-page":"1978590","DOI":"10.1155\/2018\/1978590","volume":"2018","author":"P Mi\u015bkiewicz","year":"2018","unstructured":"P. Mi\u015bkiewicz, A. Jankowska, K. Brodzi\u0144ska, J. Milczarek-Banach, U. Ambroziak, Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves\u2019 Orbitopathy. Int. J. Endocrinol. 2018, 1978590 (2018). eCollection","journal-title":"Int. J. Endocrinol."},{"key":"1823_CR9","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1007\/s00198-007-0394-0","volume":"18","author":"E Canalis","year":"2007","unstructured":"E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319\u20131328 (2007)","journal-title":"Osteoporos. Int."},{"key":"1823_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMcp1012926","volume":"365","author":"RS Weinstein","year":"2011","unstructured":"R.S. Weinstein, Glucocorticoid-Induced Bone Disease. N. Engl. J. Med. 365, 62\u201370 (2011)","journal-title":"N. Engl. J. Med."},{"key":"1823_CR11","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","volume":"13","author":"TP Staa Van","year":"2002","unstructured":"T.P. Van Staa, H.G. Leufkens, C. Cooper, The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777\u2013787 (2002)","journal-title":"Osteoporos. Int."},{"key":"1823_CR12","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","volume":"15","author":"TP Staa Van","year":"2000","unstructured":"T.P. Van Staa, H.G. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15, 993\u20131000 (2000)","journal-title":"J. Bone Miner. Res."},{"key":"1823_CR13","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/en.2003-0990","volume":"145","author":"CA O'Brien","year":"2004","unstructured":"C.A. O'Brien, D. Jia, L.I. Plotkin, T. Bellido, C.C. Powers, S.A. Stewart, S.C. Manolagas, R.S. Weinstein, Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145, 1835\u20131841 (2004)","journal-title":"Endocrinology"},{"key":"1823_CR14","first-page":"274","volume":"102","author":"RS Weinstein","year":"1998","unstructured":"R.S. Weinstein, R.L. Jilka, A.M. Parfitt, S.C. Manolagas, Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential Mech. their deleterious Eff. Bone J. Clin. Invest. 102, 274\u2013282 (1998)","journal-title":"Potential Mech. their deleterious Eff. Bone J. Clin. Invest."},{"key":"1823_CR15","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.metabol.2013.08.016","volume":"63","author":"A Tomaschitz","year":"2014","unstructured":"A. Tomaschitz, E. Ritz, B. Pieske, J. Rus-Machan, K. Kienreich, N. Verheyen, M. Gaksch, M. Gr\u00fcbler, A. Fahrleitner-Pammer, P. Mrak, H. Toplak, E. Kraigher-Krainer, W. M\u00e4rz, S. Pilz, Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism 63, 20\u201331 (2014)","journal-title":"Metabolism"},{"key":"1823_CR16","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.coph.2005.07.004","volume":"5","author":"KE Poole","year":"2005","unstructured":"K.E. Poole, J. Reeve, Parathyroid hormone - a bone anabolic and catabolic agent. Curr. Opin. Pharmacol. 5, 612\u2013617 (2005)","journal-title":"Curr. Opin. Pharmacol."},{"key":"1823_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3109\/00365513.2011.624631","volume":"72","author":"D Aslan","year":"2012","unstructured":"D. Aslan, M.D. Andersen, L.B. Gede, T.K. de Franca, S.R. J\u00f8rgensen, P. Schwarz, N.R. J\u00f8rgensen, Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans. Scand. J. Clin. Lab. Invest. 72, 14\u201322 (2012)","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"1823_CR18","doi-asserted-by":"publisher","first-page":"G92","DOI":"10.1152\/ajpgi.00317.2006","volume":"292","author":"S Huybers","year":"2007","unstructured":"S. Huybers, T.H. Naber, R.J. Bindels, J.G. Hoenderop, Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G92\u2013G97 (2007)","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"1823_CR19","first-page":"3441","volume":"81","author":"E Canalis","year":"1996","unstructured":"E. Canalis, Clinical review 83: Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81, 3441\u20133447 (1996)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1823_CR20","first-page":"1083","volume":"31","author":"B Frediani","year":"2004","unstructured":"B. Frediani, P. Falsetti, S. Bisogno, F. Baldi, C. Acciai, G. Filippou, M.R. Bacarelli, P. Filipponi, M. Galeazzi, R. Marcolongo, Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. J. Rheumatol. 31, 1083\u20131087 (2004)","journal-title":"J. Rheumatol."},{"key":"1823_CR21","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1210\/jc.2004-0164","volume":"89","author":"A Dovio","year":"2004","unstructured":"A. Dovio, L. Perazzolo, G. Osella, M. Ventura, A. Termine, E. Milano, A. Bertolotto, A. Angeli, Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis. J. Clin. Endocrinol. Metab. 89, 4923\u20134928 (2004)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1823_CR22","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1001\/archneur.1996.00550080071014","volume":"53","author":"SR Schwid","year":"1996","unstructured":"S.R. Schwid, A.D. Goodman, J.E. Puzas, M.P. McDermott, D.H. Mattson, Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch. Neurol. 53, 753\u2013757 (1996)","journal-title":"Arch. Neurol."},{"key":"1823_CR23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00198-005-1923-3","volume":"17","author":"K Natsui","year":"2006","unstructured":"K. Natsui, K. Tanaka, M. Suda, A. Yasoda, Y. Sakuma, A. Ozasa, S. Ozaki, K. Nakao, High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos. Int. 17, 105\u2013108 (2006)","journal-title":"Osteoporos. Int."},{"key":"1823_CR24","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2003.011734","volume":"63","author":"G Haugeberg","year":"2004","unstructured":"G. Haugeberg, B. Griffiths, K.B. Sokoll, P. Emery, Bone loss in patients treated with pulses of methylprednisolone is not negligible: a short term prospective observational study. Ann. Rheum. Dis. 63, 940\u2013944 (2004)","journal-title":"Ann. Rheum. Dis."},{"key":"1823_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"J.A. Kanis, L.J. Melton, C. Christiansen, C.C. Johnston, N. Khaltaev, The diagnosis of osteoporosis. J. Bone Miner. Res. 9, 1137\u20131141 (1994)","journal-title":"J. Bone Miner. Res."},{"key":"1823_CR26","doi-asserted-by":"publisher","first-page":"319","DOI":"10.5603\/EP.2013.0012","volume":"64","author":"P P\u0142udowski","year":"2013","unstructured":"P. P\u0142udowski, E. Karczmarewicz, M. Bayer, G. Carter, D. Chlebna-Sok\u00f3\u0142, J. Czech-Kowalska, R. D\u0119bski, T. Decsi, A. Dobrza\u0144ska, E. Franek, P. G\u0142uszko, W.B. Grant, M.F. Holick, L. Yankovskaya, J. Konstantynowicz, J.B. Ksi\u0105\u017cyk, K. Ksi\u0119\u017copolska-Or\u0142owska, A. Lewi\u0144ski, M. Litwin, S. Lohner, R.S. Lorenc, J. Lukaszkiewicz, E. Marcinowska-Suchowierska, A. Milewicz, W. Misiorowski, M. Nowicki, V. Povoroznyuk, P. Rozentryt, E. Rudenka, Y. Shoenfeld, P. Socha, B. Solnica, M. Szalecki, M. Ta\u0142a\u0142aj, S. Varbiro, M.A. \u017bmijewski, Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe - recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynol. Pol. 64, 319\u2013327 (2013)","journal-title":"Endokrynol. Pol."},{"key":"1823_CR27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.20452\/pamw.1301","volume":"122","author":"T Gasi\u0144ska","year":"2012","unstructured":"T. Gasi\u0144ska, A. Borowska, H. Wichary, R. Dec, Effect of methylprednisolone pulse therapy with and without alendronate on biochemical markers of bone turnover in patients with Graves' ophthalmopathy. Pol. Arch. Med. Wewn. 122, 341\u2013347 (2012)","journal-title":"Pol. Arch. Med. Wewn."},{"key":"1823_CR28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF03343976","volume":"25","author":"P Ardissone","year":"2002","unstructured":"P. Ardissone, E. Rota, L. Durelli, P. Limone, G.C. Isaia, Effects of high doses of corticosteroids on bone metabolism. J. Endocrinol. Invest. 25, 129\u2013133 (2002)","journal-title":"J. Endocrinol. Invest."},{"key":"1823_CR29","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1136\/ard.45.9.757","volume":"45","author":"JW Bijlsma","year":"1986","unstructured":"J.W. Bijlsma, S.A. Duursma, O. Huber-Bruning, Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Ann. Rheum. Dis. 45, 757\u2013760 (1986)","journal-title":"Ann. Rheum. Dis."},{"key":"1823_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-014-0012-0","volume":"7","author":"D Tuchendler","year":"2014","unstructured":"D. Tuchendler, M. Bolanowski, The influence of thyroid dysfunction on bone metabolism. Thyroid Res. 7, 12 (2014)","journal-title":"Thyroid Res."},{"key":"1823_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2015-2175","volume":"101","author":"CF Munns","year":"2016","unstructured":"C.F. Munns, N. Shaw, M. Kiely, B.L. Specker, T.D. Thacher, K. Ozono, T. Michigami, D. Tiosano, M.Z. Mughal, O. M\u00e4kitie, L. Ramos-Abad, L. Ward, L.A. DiMeglio, N. Atapattu, H. Cassinelli, C. Braegger, J.M. Pettifor, A. Seth, H.W. Idris, V. Bhatia, J. Fu, G. Goldberg, L. S\u00e4vendahl, R. Khadgawat, P. Pludowski, J. Maddock, E. Hypp\u00f6nen, A. Oduwole, E. Frew, M. Aguiar, T. Tulchinsky, G. Butler, W. H\u00f6gler, Global Consensus Recommendations on Prevention and Management of Nutritional Rickets. J. Clin. Endocrinol. Metab. 101, 394\u2013415 (2016)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1823_CR32","first-page":"955","volume":"78","author":"P Garnero","year":"1994","unstructured":"P. Garnero, V. Vassy, A. Bertholin, J.P. Riou, P.D. Delmas, Markers of bone turnover in hyperthyroidism and the effects of treatment. J. Clin. Endocrinol. Metab. 78, 955\u2013959 (1994)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1823_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/105072503322238854","volume":"13","author":"P Vestergaard","year":"2003","unstructured":"P. Vestergaard, L. Mosekilde, Hyperthyroidism, bone mineral, and fracture risk \u2013 a meta-analysis. Thyroid 13, 585\u2013593 (2003)","journal-title":"Thyroid"},{"key":"1823_CR34","first-page":"753","volume":"82","author":"A Siddiqi","year":"1997","unstructured":"A. Siddiqi, J.M. Burrin, K. Noonan, I. James, D.F. Wood, C.P. Price, J.P. Monson, A longitudinal study of markers of bone turnover in Graves\u2019 disease and their value in predicting bone mineral density. J. Clin. Endocrinol. Metab. 82, 753\u2013759 (1997)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1823_CR35","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/j.1365-2265.2004.02110.x","volume":"61","author":"H Karga","year":"2004","unstructured":"H. Karga, P.D. Papapetrou, A. Korakovouni, F. Papandroulaki, A. Polymeris, G. Pampouras, Bone mineral density in hyperthyroidism. Clin. Endocrinol. (Oxf.). 61, 466\u2013472 (2004)","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"1823_CR36","doi-asserted-by":"publisher","first-page":"8","DOI":"10.7326\/0003-4819-120-1-199401010-00002","volume":"1","author":"T Diamond","year":"1994","unstructured":"T. Diamond, J. Vine, R. Smart, P. Butler, Thyrotoxic bone disease in women: a potentially reversible disorder. Ann. Intern. Med. 1, 8\u201311 (1994)","journal-title":"Ann. Intern. Med."},{"key":"1823_CR37","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-09-0139","volume":"161","author":"A Svare","year":"2009","unstructured":"A. Svare, T.I. Nilsen, T. Bj\u00f8ro, S. Forsmo, B. Schei, A. Langhammer, Hyperthyroid levels of TSH correlate with low bone mineral density: the HUNT 2 study. Eur. J. Endocrinol. 161, 779\u2013786 (2009)","journal-title":"Eur. J. Endocrinol."},{"key":"1823_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1507\/endocrj.48.63","volume":"48","author":"H Yamashita","year":"2001","unstructured":"H. Yamashita, S. Noguchi, K. Takatsu, E. Koike, T. Murakami, S. Watanabe, S. Uchino, H. Yamashita, H. Kawamoto, High prevalence of vitamin D deficiency in Japanese female patients with Graves' disease. Endocr. J. 48, 63\u201369 (2001)","journal-title":"Endocr. J."},{"key":"1823_CR39","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1002\/1529-0131(199908)42:8<1740::AID-ANR25>3.0.CO;2-E","volume":"42","author":"S Amin","year":"1999","unstructured":"S. Amin, M.P. LaValley, R.W. Simms, D.T. Felson, The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 42, 1740\u20131751 (1999)","journal-title":"Arthritis Rheum."},{"key":"1823_CR40","first-page":"1","volume":"2","author":"J Homik","year":"2000","unstructured":"J. Homik, M.E. Suarez-Almazor, B. Shea, A. Cranney, G. Wells, P. Tugwell, Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst. Rev. CD000952 2, 1\u201314 (2000).","journal-title":"Cochrane Database Syst. Rev. CD000952"},{"key":"1823_CR41","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acr.23279","volume":"69","author":"L Buckley","year":"2017","unstructured":"L. Buckley, G. Guyatt, H.A. Fink, M. Cannon, J. Grossman, K.E. Hansen, M.B. Humphrey, N.E. Lane, M. Magrey, M. Miller, L. Morrison, M. Rao, A. Byun Robinson, S. Saha, S. Wolver, R.R. Bannuru, E. Vaysbrot, M. Osani, M. Turgunbaev, A.S. Miller, T. McAlindon, 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 69, 1095\u20131110 (2017)","journal-title":"Arthritis Care Res."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1823-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-018-1823-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-018-1823-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T07:56:34Z","timestamp":1775289394000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-018-1823-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,1]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["1823"],"URL":"https:\/\/doi.org\/10.1007\/s12020-018-1823-x","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,1]]},"assertion":[{"value":"14 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed and written consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}